Achieving Remission and Favorable Outcomes in Patients with Depression/Anxiety and Substance use Disorders

CNS Spectrums

Volumn 13, Issue S6, 2008, Pages 10-12

  Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION; ANXIETY DISORDER; COMORBIDITY; HUMAN; MAJOR DEPRESSION; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE; REMISSION; REVIEW; TIME; TREATMENT OUTCOME;

ANXIETY DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; HUMANS; RECURRENCE; REMISSION INDUCTION; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 65349154555     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900002911     Document Type: Article

References (35)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Substance Use Disorders. 2nd ed. New York, NY: American Psychiatric Association; 2006.
2. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2004: 372–474.
3. Yonkers, KA, Warshaw, MG, Massion, AO, Keller, MB. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry. 1996; 168(3):308–313.
4. Lehman, AF, Myers, CP, Corty, E. Assessment and classification of patients with psychiatric and substance abuse syndromes. Psychiatr Serv. 2000; 51(9):1119–1125.
5. Hasin, D, Liu, X, Nunes, E, McCloud, S, Samet, S, Endicott, J. Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry. 2002; 59(4):375–380.
6. Compton, WM 3rd, Cottler, LB, Jacobs, JL, Ben-Abdallah, A, Spitznagel, EL. The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry. 2003; 160(5):890–895.
7. Charney, DA, Palacios-Boix, J, Negrete, JC, Dobkin, PL, Gill, KJ. Association between concurrent depression and anxiety and six-month outcome of addiction treatment. Psychiatr Serv. 2005; 56(8):927–933.
8. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000; 157(4 Suppl):1–45.
9. Kessler, RC, Berglund, P, Demler, O, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23):3095–3105.
10. Fricchione, G. Generalized anxiety disorder. N Engl J Med. 2004; 351(7):675–682.
11. Physicians Desk Reference 2006: Guide to Drug Interactions, Side Effects, and Indications. 60th ed. Montvale, NJ: Thomson PDR; 2006: 1177–3418.
12. Brady, KT. Evidence-Based Pharmacotherapy for Mood and Anxiety Disorders with Concurrent Alcoholism. CNS Spectr. 2008; 13: 4(Suppl 6):7–9.
13. Davidson, JR, Bose, A, Wang, Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2005; 66(11):1441–1446.
14. Allgulander, C, Huusom, AK, Florea, I. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006; 9(5):495–505.
15. Stocchi, F, Nordera, G, Jokinen, RH, et al. Efficacy and tolerability of paroxetine for the longterm treatment of generalized anxiety disorder. J Clin Psychiatry. 2003; 64(3):250–258.
16. Bielski, RJ, Bose, A, Chang, CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry. 2005; 17(2):65–69.
17. Montgomery, SA, Sheehan, DV, Meoni, P, Haudiquet, V, Hackett, D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res. 2002; 36(4):209–217.
18. Suh, JJ, Pettinati, HM, Kampman, KM, O'Brien, CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006; 26(3):290–302.
19. Naranjo, CA, Sellers, EM. Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers. Recent Dev Alcohol. 1989: 7: 255–266.
20. Kranzler, HR, Mueller, T, Cornelius, J, et al. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 2006; 26(1):13–20.
21. Krampe, H, Stawicki, S, Wagner, T, et al. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res. 2006: 30(1):86–95.
22. Anton, RF, O'Malley, SS, Ciraulo, DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006; 295(17):2003–2017.
23. Pelc, I, Le Bon, O, Verbanck, P, Lehert, PH, Opsomer, L. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients: A placebo-controlled double-blind multicentre study. In: Naranjo, C, Sellers, E, ed. Novel Pharmacological Interventions for Alcoholism. New York, NY: Springer-Verlag; 1992: 348–352.
24. Ladewig, D, Knecht, T, Leher, P, Fendl, A. Acamprosate--a stabilizing factor in long-term withdrawal of alcoholic patients (in German). Ther Umsch. 1993; 50(3):182–188.
25. Geerlings, PJ, Ansoms, C, van den Brink, W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res. 1997; 3: 129–137.
26. Poldrugo, F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction. 1997; 92(11):1537–1546.
27. Chick, J, Howlett, H, Morgan, MY, Ritson, B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000; 35(2):176–187.
28. Tempesta, E, Janiri, L, Bignamini, A, Chabac, S, Potgieter, A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. 2000; 35(2):202–209.
29. Gual, A, Lehert, P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol. 2001; 36(5):413–418.
30. Mason, BJ, Goodman, AM, Chabac, S, Lehert, P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006; 40(5):383–393.
31. Barrias, JA, Chabac, S, Ferreira, L, Fonte, A, Potgieter, AS, Teixeira de Sousa, E. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatr. Clín. 1997; 18: 149–160.
32. Paille, FM, Guelfi, JD, Perkins, AC, Royer, RJ, Steru, L, Parot, P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995; 30(2):239–247.
33. Sass, H, Soyka, M, Mann, K, Zieglgänsberger, W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996; 53(8):673–680.
34. Whitworth, AB, Fischer, F, Lesch, OM, et al. Comparison of acamprosate and placebo in longterm treatment of alcohol dependence. Lancet. 1996; 347(9013):1438–1442.
35. Besson, J, Aeby, F, Kasas, A, Lehert, P, Potgieter, A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998; 22(3):573–579.